Remus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Remus Pharmaceuticals has a total shareholder equity of ₹191.4M and total debt of ₹79.4M, which brings its debt-to-equity ratio to 41.5%. Its total assets and total liabilities are ₹346.6M and ₹155.3M respectively. Remus Pharmaceuticals's EBIT is ₹106.7M making its interest coverage ratio -73.8. It has cash and short-term investments of ₹30.4M.
Key information
41.5%
Debt to equity ratio
₹79.43m
Debt
Interest coverage ratio | -73.8x |
Cash | ₹30.38m |
Equity | ₹191.36m |
Total liabilities | ₹155.26m |
Total assets | ₹346.61m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: REMUS's short term assets (₹113.4M) exceed its short term liabilities (₹81.6M).
Long Term Liabilities: REMUS's short term assets (₹113.4M) exceed its long term liabilities (₹73.6M).
Debt to Equity History and Analysis
Debt Level: REMUS's net debt to equity ratio (25.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if REMUS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: REMUS's debt is well covered by operating cash flow (66.9%).
Interest Coverage: REMUS earns more interest than it pays, so coverage of interest payments is not a concern.